Ever-greening: A status check in selected countries

Journal of Generic Medicines

Volumn 7, Issue 3, 2010, Pages 227-242

  Rathod, Sandeep Kanak ^a  

^a 503 RadheShyam Apartments ^*  (India)

Author keywords

Australia; Canada; Ever greening; India; Patent linkage; Patents; Philippines; Thailand

Indexed keywords

ALENDRONIC ACID; AMLODIPINE; AMLODIPINE BESYLATE; ATORVASTATIN; AZITHROMYCIN; CITALOPRAM; CLOPIDOGREL; DASATINIB; ERLOTINIB; ESOMEPRAZOLE; GANCICLOVIR; GENERIC DRUG; IMATINIB; LOPINAVIR PLUS RITONAVIR; NEW COVERSYL; OLANZAPINE; OMEPRAZOLE; PERINDOPRIL; PREGABALIN; SORAFENIB; TULATHROMYCIN; UNCLASSIFIED DRUG; VALGANCICLOVIR; VARENICLINE;

AUSTRALIA; CANADA; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; GOVERNMENT; INDIA; LAW; LAW SUIT; PATENT; PHILIPPINES; REVIEW; THAILAND;

EID: 77955702668     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/jgm.2010.14     Document Type: Review

References (76)

1. European Generics Association. ( 2010 ) http://www .egagenerics.com/gen- evergrn.htm , accessed 11 February, 2010.
2. Faunce , T. A. and Lexchin , J. ( 2007 ) ' Linkage ' pharmaceutical ever greening in Canada and Australia (June 1, 2007). Australia and New Zealand Journal of Health Policy 1 (4) : 8 , June 2007, http:// ssrn.com/abstract= 1405010 , accessed 11 February.
3. From the European Competition Commission website , http://ec.europa.eu/ competition/sectors/ pharmaceuticals/overview-en.html , accessed 20 February 2010.
4. Glaxo , http://www.gsk.com/policies/GSK-andevergreening. pdf , accessed 11 February, 2010.
5. Pfi zer's blockbuster product - Atorvastatin Calcium (Lipitor ® ) - has a plethora of patents on various crystalline forms, including one patent for crystalline Forms I, IV listed on the Orange Book.
6. For, for example, Desloratadine (Clarinex ® ) from Loratadine (Claritin ® ).
7. For, for example Eszopiclone (Lunesta ® ) from Zopiclone (Imovane ® ).
8. Abbott's Fenofi brate (Tricor ® ) capsules were earlier sold in 54 mg and 160 mg; and this was later changed to 54 mg and 160 mg tablets (Tricor ® ), and which was again changed to 48 mg and 145 mg.
9. For, for example, Venlafaxine immediate release tablets (Effexor ® ) to an extended release version (Effexor XR ® ).
10. For instance, US patent 6,333,198 for substantially pure Lamotrigine.
11. For instance, US patent 6,469,012 for use of Sildenafi l Citrate in erectile dysfunction.
12. US patent 6, 419,958, covering therapeutic blood plasma concentration of venlafaxine over a 24h period.
13. For instance, US patent 6, 455,574 covers use of Atorvastatin and Amlodipine, marketed as Caduet ® .
14. US patent 6,784,177 marketed as BiDil ® .
15. Astra switched from racemic Omeprazole (Prilosec ® ) to Esomeprazole (Nexium ® ) which is the S-enantiomer of the racemic product, with an unprecedented advertisement blitzkrieg - ' the Purple pill '.
16. Staton , T. ( 2009 ) Cephalon hikes Provigil price to push new med. Fierce pharma , 22 December 2009, http://www.fi ercepharma.com/story/ cephalonhikes- provigil-price-push-new-med/2009-12-22 , accessed 19 March 2010.
17. For instance, GlaxoSmithkline timed the issuance and listing of multiple patents for the drug Paroxetine (Paxil ® ) on the Orange Book, to get four successive 30-month stays to delay the approval for a generic version. The fi rst stay for FDA approval expired in November 2000, but the US FDA was not able to approve a generic version of Paxil until September 2003.
18. For instance, the US House Judiciary Committee's Subcommittee on Courts and Competition Policy held hearings on related issues in June 2009.
19. Annual Report of the Commissioner of Competition ; March 2004; page 63. Report available online at http://www.competitionbureau.gc.ca/eic/site/ cb-bc.nsf/vwapj/ct03001e-annualreport.pdf/ $ fi le/ ct03001e- annualreport.pdf , accessed 20 February 2010.
20. AstraZeneca Canada Inc. v. Canada (Minister of Health) , (2006) 2 S.C.R. 560, 2006 SCC 49.
21. Apotex Inc. v. Sanofi -Synthelabo Canada Inc. , 2008 SCC 61.
22. Eli Lilly Canada Inc. v. Novopharm ltd. , 2009 FC 1018.
23. National Post , October 2009; online edition, http://www.nationalpost. com/story-printer. html?id=2094604 , accessed 14 October 2009.
24. The medicines in question were omeprazole, amlodipine, doxazosin, loratadine, mirtazapine and ramipril. The cost numbers come from a British Generic Manufacturers Association submission to the Health Committee of the House of Commons. Details are available in ' The Infl uence of the Pharmaceutical Industry ' , Fourth Report on 2004-5 session, published on 5 April 2005 (page 92). The Report is available online at http://www. publications.parliament.uk/pa/cm200405/cmselect/ cmhealth/42/42.pdf , accessed 26 February 2010.
25. EWCA. ( 2008 ) Civ 445.
26. Meirion , J. ( 2008 ) Gaviscon maker ' cheated the NHS ' BBC report. 7 March 2008, http://news.bbc .co.uk/2/hi/uk-news/7282627.stm , accessed 11 February 2010.
27. Hughes , D. A. and Ferner , R. E. ( 2010 ) New drugs for old: Disinvestment and NICE. BMJ 340 : c572 , http://www.bmj.com/cgi/content/full/ 340/feb25- 1/c572 # REF13 , accessed 27 February 2010.
28. AstraZeneca v Commission Case T-321/05 (2005/C 271/47), decision available at http://ec.europa.eu/ competition/antitrust/cases/decisions/37507/ en.pdf , accessed 20 February 2010.
29. European Commission Press release. ( 2005 ) Competition: Commission fi nes AstraZeneca S 60 million for misusing patent system to delay market entry of competing generic drugs, 15 June 2005. http://europa.eu/rapid/ pressReleasesAction .do?reference=IP/05/737 & format=HTML & aged=0 & language=EN & guiLanguage=en , accessed 20 February 2010.
30. European Competition Commission (ECC). ( 2010 ) http://ec.europa.eu/ competition/sectors/ pharmaceuticals/overview-en.html , accessed 11 February 2010.
31. IN207232.
32. IN201140.
33. IN202128.
34. IN201649.
35. IN219034.
36. IN210420.
37. Novartis ' Indian Application: 1602/MAS/1998 for a polymorph of Imatinib Mesylate.
38. From an unpublished study by Basheer, Shamnad and Guha, Souvik; details available online at http:// spicyipindia.blogspot.com/2009/09/patent- oppositionsin- india-effi cacy-of.html , accessed 11 February 2010.
39. According to the US Federal Trade Commission's 2002 study titled ' Generic Drug Entry: Prior to Patent Expiration ' , generic applicants prevailed in 29 out of 40 drug product litigations (or 73 per cent). This study is available online at www.ftc.gov/ os/2002/07/genericdrugstudy.pdf , accessed 11 February 2010.
40. For instance, Abbott when faced with pre-grant opposition for its application (339/MUMNP/2006) covering heat stable formulation of Lopinavir+ Ritonavir, fi led not one, but two divisional applications at two different patent offi ces - 726/ MUMNP/2009 at Mumbai Patent Offi ce and 2474/ DELNP/2009 at Delhi Patent Offi ce - with exactly same set of claims as the parent, on the day of the opposition hearing for the parent ' 339.
41. Gilead lost its application: 2076/Del/1997 covering Tenofovir disoproxil in an opposition, but fi led a divisional - 602/DEL/2007 with similar scope; similarly its application 896/del/2002 covering Tenofovir disoproxil fumarate was rejected, but it has 1135/DEL/2007 pending, covering similar scope.
42. For instance, Glaxo abandoned its original fi ling for Atazanavir (805/MAS/1997) but is prosecuting core claims in a later divisional - 310/CHE/2007.
43. Gilead has adopted this multiple divisional fi ling strategy for Tenofovir, not only in India, but also in Brazil as well. Read: Amin , T. ( 2008 ) Brazilian patent offi ce confi rms refusal of tenofovir patent application. Web article on I-mak website, http:// www.i-mak.org/i-mak-blog-updates/2008/9/3/ brazilian-patent-offi ce-confi rms-refusal-of-tenofovirpatent. html , accessed 11 February 2010.
44. IN203937.
45. CS(OS) No. 2680/2008, order dated 19 December 2008.
46. Vide Order dated 07 November 2008 in WP(C) No. 7833/2008
47. Order dated 18 August 2009.
48. Apiradee , T. ( 2008 ) Thailand, civic move to halt evergreen patents. Bangkok Post , 10 June 2008. Archived text available at http://www.iprasia.org/ site/latest-news/ipr.htm?mode=view & num=62 & pag e=9 & pPart= & pKeyword= & pGroup= , accessed 11 February 2010.
49. White Paper by the Ministry of Public Health (Thailand) and The National Health Security Offi ce, Thailand (2007). http://www.moph.go.th/hot/ White%20Paper%20CL-EN.pdf , accessed 11 February 2010.
50. Rathod , S. ( 2008 ) Thailand: Finally, the CLs will not be revoked ... Sasomsab turns around. 10 March 2008, http://genericpharmaceuticals.blogspot. com/2008/03/thailand-fi nally-cls-will-not-be.html , accessed 11 February 2010.
51. CL issued in January 2007.
52. Alcorn , K. ( 2007 ) Abbott to withhold new drugs from Thailand in retaliation for Kaletra compulsory license. Aidsmap article , 15 March 2007, http:// www.aidsmap.com/en/news/00C7641B-57F5- 4AB8-8876-9040425D4464.asp , accessed 11 February 2010.
53. Balakrishnan , R. ( 2007 ) Sanofi to sue Emcure for alleged patent violation in Thailand. The Financial Express 03 September 2007, http://www .fi nancialexpress.com/printer/news/214283/ , accessed 11 February 2010.
54. Mukherjee , R. ( 2008 ) Pharma fi rms under US pressure to stop generic sale. The Times of India 13 February 2008, http://timesofi ndia.indiatimes.com/ India-Business/Pharma-fi rms-under-US-pressure- to-stop-generic-sale/ articleshow/2777692.cms , accessed 11 February 2010.
55. Letter by Susan Schwab to Senator Thomas Allen, dated 17 January 2007. Copy available at http:// www.cptech.org/ip/health/c/thailand/letter.pdf , accessed 11 February 2010.
56. Professor Baker , B. K. ( 2007 ) Standing up to Abbott's decision to withhold registration and marketing of life-saving medicines - A new variant of pharmaceutical apartheid. Health GAP , 13 March 2007. Note available online at http:// www.twnside.org.sg/title2/FTAs/info.service/ fta.info.service083.htm , accessed 11 February 2010.
57. Report of a WHO Mission. ( 2008 ) Improving access to medicines in Thailand: The use of TRIPS fl exibilities , http://www.moph.go.th/hot/ THAIMissionReport%20 FINAL15feb08.pdf , accessed 11 February 2010.
58. Gerhardsen , T. I. S. ( 2006 ) Pfi zer fi ghts IP fl exibilities in the Philippines. PHM Article , http://www. phmovement.org/en/node/186 , accessed 11 February 2010.
59. Pacifi c Bridge Medical newsletter. ( 2008 ) Philippine president signs cheaper medicines act. 5 August 2008, http://www.pacifi cbridgemedical.com/ newsletter/ article.php?id=371 , accessed 11 February 2010.
60. Ollier , P. ( 2008 ) Philippines plans to follow India in limiting patentability. Managing Intellectual Property , 6 May 2008. http://www. managingip.com/Article/ 1927492/Philippines-plans-to-follow-India-inlimiting- patentability.html , accessed 11 February 2010.
61. Philippine patent No. 29,149 - same as US patent 52,73,995 and its equivalents. This enantiomer patent has been focus of litigation in various countries around the world and invalidated in Australia, Austria, the Netherlands, Norway, South Korea, Germany and the United Kingdom.
62. Cruz , N. ( 2009 ) As i see it: RP should crack down on monopolies, cartels. Inquirer , 1 November 2009, http://services.inquirer.net/print/print. php?article- id=20091101-233491 , accessed 11 February 2010.
63. Ho , A. L. ( 2009 ) Pfi zer-Unilab row reaches retail sector. Philippine Daily Inquirer , 25 October 2009, http://business.inquirer.net/money/topstories/ view/20091025-232217/Pfi zer-Unilab-row-reachesretail- sector , accessed 11 February 2010.
64. Hermosa , J. A. D. ( 2010 ) Pfi zer suffers setback in its campaign against generic anti-cholesterol drug. Business World , 11 February 2010, http://www .bworldonline.com/main/content.php?id=6214 , accessed 11 February 2010.
65. Ho , A. L. ( 2009 ) Unilab readies new patent invalidation case against Pfi zer. Philippine Daily Inquirer , 15 February 2010, http://business.inquirer. net/money/topstories/view/20100215-253413/ Unilab-readies-new-patent- invalidation-case-against- Pfi zer , accessed 16 February 2010.
66. This is possibly RP 1199653719; based on Author's search.
67. Balita website, http://balita.ph/2009/10/27/ unilab-vows-to-launch-more- branded-genericdrugs/ , accessed 11 February 2010.
68. Isip , I. ( 2010 ) Unilab to challenge more patents to bring down prices. Malaya Business Insight , 16 February 2010, http://www.malaya.com. ph/02162010/busi5.html , accessed 17 February 2010.
69. Unilab to challenge more Pfi zer patents. Business World 15 February 2010, http://www.bworldonline. com/main/content.php?id=6339 , accessed 17 February 2010.
70. Aktiebolaget Hassle v Alphapharm Pty Ltd, 212 CLR 411 2002.
71. Chalmers , R. ( 2006 ) Evergreen or deciduous ? Australian trends in relation to the ' evergreening ' of patents. Melbourne University Law Review 30 (1) , http://www.austlii.edu.au/au/journals/MULR/ 2006/2.html , accessed 07 May 2010.
72. Article 17.10.4 of the AU US FTA.
73. Arrow Pharmaceuticals Ltd v Merck & Co Inc (2004) FCA 1282.
74. Apotex Ltd. (formerly GenRx Pty Ltd) v Les Laboratoires Servier (No 2) (2008) FCA 607.
75. Faunce , T. ( 2008 ) New forms of evergreening in Australia: Misleading advertising, enantiomers and data exclusivity: Apotex v Servier and Alphapharm v Lundbeck. Medical Law Reporter, Journal of Law Medicine 16 : 220.
76. Alphapharm Pty Ltd v H Lundbeck A/s (2008) 76 IPR 618; (2008) FCA 559.